甲磺酸阿帕替尼片联合替吉奥治疗老年进展期胃癌患者的临床研究  

Clinical study of apatinib mesylate tablets combined with tegafur in the treatment of advanced gastric cancer in elderly patients

作　　者：孔炯[1] 顾玉兰[1] 王胤华 KONG Jiong;GU Yu-lan;WANG Yin-hua(Changshu Second People's Hospital,Suzhou 215500,China)

机构地区：[1]江苏苏州常熟市第二人民医院,215500

出　　处：《中国实用医药》2024年第10期109-111,共3页China Practical Medicine

摘　　要：目的 研究甲磺酸阿帕替尼片联合替吉奥治疗老年进展期胃癌患者的效果。方法 选择老年进展期胃癌患者60例,将所有研究对象进行随机数字序号编码,最终确认序号编排为1~30患者为对照组,序号编排为31~60患者为研究组。对照组患者接受替吉奥治疗,研究组患者接受甲磺酸阿帕替尼片联合替吉奥治疗。对比两组临床治疗效果,不良反应发生情况,治疗后第1、2、3年的生存情况。结果 研究组的缓解率53.33%、控制率80.00%高于对照组的16.67%、46.67%(P<0.05)。研究组不良反应发生率为26.67%,对照组则为20.00%,对比无统计学意义(P>0.05)。对照组第2、3年生存20例(66.67%)和18例(60.00%),研究组则为27例(90.00%)和25例(83.33%),研究组第2、3年生存率高于对照组(P<0.05)。两组第1年生存率比较无统计学意义(P>0.05)。结论 老年进展期胃癌患者在甲磺酸阿帕替尼片联合替吉奥治疗后,显著缓解并控制了疾病的进展,不会增加不良反应的发生,并延长生存时间,值得临床推广。Objective To study the effect of apatinib mesylate tablets combined with tegafur in the treatment of advanced gastric cancer in elderly patients.Methods A total of 60 elderly patients with advanced gastric cancer were selected,and all subjects were randomly coded.The sequence number of patients in the control group was confirmed to be 1-30,and the sequence number of patients in the study group was confirmed to be 31-60.Patients in control group were treated with tegafur,and patients in the study group received apatinib mesylate tablets combined with tegafur.The clinical effects,occurrence of adverse reactions and survival status at the 1st,2nd and 3rd year after treatment were compared between the two groups.Results The remission rate of 53.33%and control rate of 80.00%in the study group were higher than 16.67%and 46.67%in the control group(P<0.05).The incidence of adverse reactions was 26.67%in the study group and 20.00%in the control group,and there was no statistical significance in comparison(P>0.05).At the 2nd and 3rd year,20 cases(66.67%)and 18 cases(60.00%)survived in the control group,while 27 cases(90.00%)and 25 cases(83.33%)survived in the research group,and the survival rates at 1st,2nd and 3rd year after treatment in the study group were higher than those in the control group(P<0.05).There was no statistical significance in the 1-year survival rate between the two groups(P>0.05).Conclusion Apatinib mesylate tablets combined with tegafur can significantly alleviate and control the progression of the disease in elderly patients with advanced gastric cancer,without increasing the occurrence of adverse reactions,and prolong the survival time,which is worthy of clinical promotion.

关 键 词：进展期胃癌 甲磺酸阿帕替尼片 替吉奥 病症控制情况 老年 

分 类 号：R735.2[医药卫生—肿瘤]